Cargando…
BEZ235: When Promising Science Meets Clinical Reality
An article in a recent issue of The Oncologist reports the results of a phase I clinical trial of BEZ235 in patients with advanced renal cell carcinoma. The study was terminated early due to toxicity and a lack of clinical efficacy. The rapid and concise publication of this type of clinical result i...
Autores principales: | Pongas, Georgios, Fojo, Tito |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016067/ https://www.ncbi.nlm.nih.gov/pubmed/27566248 http://dx.doi.org/10.1634/theoncologist.2016-0243 |
Ejemplares similares
-
Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal Cancer
por: Chen, Yu-Hsuan, et al.
Publicado: (2019) -
NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma
por: Huang, Jin-Cheng, et al.
Publicado: (2017) -
Activity of BKM120 and BEZ235 against Lymphoma Cells
por: Civallero, Monica, et al.
Publicado: (2015) -
Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models
por: Netland, I. A., et al.
Publicado: (2016) -
Antitumor efficacy of liposome-encapsulated NVP-BEZ 235 in combination with irreversible electroporation
por: Tian, Li, et al.
Publicado: (2018)